Posted by Michael Wonder on 20 Apr 2022
New drug application resubmission update
20 April 2022 - Polarean Imaging announces that further to the RNS issued on 31 March 2022, the Company can confirm that the US FDA has accepted the resubmission of its new drug application as a complete response, and has established a user fee goal date of 30 September 2022, designating it Type 2.
